Tonix Pharmaceuticals Holding Corp. TNXP
4.10 USD -0.39 (-8.69%)
At closeNov 11, 2026, 4:00 AM EST
4.19 +0.09 +2.20%
Pre-market · Nov 11, 4:00 AM ET
4.07 Day range 4.57
4.00 52-week range 20.56
- YTD
- -73.75%
- 1 year
- -76.61%
News
marketbeat.com Tonix Pharmaceuticals' TONMYA Sales Jump 37% as Insurance Coverage Expands Tonix Pharmaceuticals NASDAQ: TNXP said sales of its fibromyalgia treatment TONMYA rose 37% in the third quarter, as the company expanded insurance access and increased its sales force.
seekingalpha.com Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2026 Earnings Call Transcript Tonix Pharmaceuticals Holding Corp. (TNXP) Q3 2026 Earnings Call Transcript
marketbeat.com What Tonix Pharmaceuticals (TNXP) Said on Its Q3 Earnings Call Tonix Pharmaceuticals NASDAQ: TNXP reported approximately $15 million in third-quarter sales of its fibromyalgia drug TONMYA, up 37% from the previous quarter, as insurance coverage expanded and…
benzinga.com Tonix Pharmaceuticals Q3 2026 Earnings Call Transcript Tonix Pharmaceuticals (NASDAQ:TNXP) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
benzinga.com Tonix Pharmaceuticals Q3 EPS $(2.89) Misses $(2.31) Estimate, Sales $17.200M Beat $16.717M Estimate Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.89) per share which missed the analyst consensus estimate of $(2.31) by 25.11 percent. This is a 19.5 percent increase over losses…
globenewswire.com Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational Highlights Third quarter TONMYA® net sales of approximately $15 million, up 37% from the second quarter Approximately $163 million in cash and cash equivalents as of September 30, 2026 Strategic focus on…
globenewswire.com Tonix Pharmaceuticals to Present at Guggenheim's 3rd Annual Healthcare Innovation Conference BERKELEY HEIGHTS, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or “the Company”), a fully integrated, commercial-stage biopharmaceutical…
benzinga.com Tonix Pharma Presents Data From Analysis Of Phase 3 RELIEF And RESILIENT Studies Of TONMYA For Treatment Of Fibromyalgia In Adults, At IASP 2026 World Congress TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studiesTonix…
benzinga.com Canaccord Genuity Initiates Coverage On Tonix Pharmaceuticals with Buy Rating, Announces Price Target of $18 Canaccord Genuity analyst Gary Nachman initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy rating and announces Price Target of $18.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
benzinga.com Tonix Pharmaceuticals To Present Effects Of TONMYA On Fibromyalgia Symptoms And Physical Function At The World Congress On Pain, October 26-30 TONMYA was approved by the U.S. Food and Drug Administration on August 15, 2025, and commercially launched in the U.S. on November 17, 2025.Poster Presentation DetailsTitle: Cyclobenzaprine HCl…